Melanotan II Side Effects: Why Regulators Warn Against It
Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It is marketed online for tanning and is sold by unlicensed sellers. It is not approved by any regulator. The UK Medicines and Healthcare products Regulatory Agency (MHRA), the Australian Therapeutic Goods Administration (TGA), and other agencies have warned the public against use. Reported adverse events include new and changing moles, melanoma case reports, priapism, and serious infections from non-sterile injection.
Melanotan II is not FDA-approved and lacks controlled human safety data. Not approved anywhere. UK MHRA has issued public warnings. TGA classifies it as an unlicensed and unsafe substance. Case reports describe melanoma diagnoses following melanotan II use. This page summarises the published literature and regulator positions. It is not medical advice.
Key Takeaways
- Melanotan II is not approved anywhere in the world.
- The UK MHRA and Australian TGA have issued public warnings against use.
- Published case reports describe melanoma diagnoses, new and changing moles, priapism, and serious infections from non-sterile injection.
- It is sold by unlicensed sellers; product purity and content are unknown.
What is Melanotan II, and what is it marketed for?
Melanotan II. Melanotan II is a non-selective melanocortin receptor agonist (binding MC1R through MC5R). It stimulates melanocyte activity, which increases skin pigmentation, but also affects sexual function, appetite, and other melanocortin-mediated processes.
What side effects and safety concerns have been reported?
The summary below draws from the published literature and regulator statements. Severity classification follows the source documents.
| Concern | What has been reported | Source |
|---|---|---|
| New and changing moles, melanoma case reports | Published case reports describe rapidly evolving naevi and melanomas after melanotan II use | MHRA-cited concern |
| Priapism | Prolonged painful erection requiring emergency care | Melanocortin-pathway adverse event |
| Nausea, vomiting, flushing, severe facial pigmentation | Common acute reactions | MHRA case-report literature |
| Serious infections from non-sterile injection | Sepsis, abscess, infective endocarditis case reports | Unlicensed product sold via underground channels |
| Cardiovascular effects | Tachycardia, hypertension, palpitations reported | Case reports |
| No regulator approval anywhere | Unlicensed sale and use | Active public-safety warnings |
Taking Melanotan II alongside prescription medicines?
Allmeds scans interactions across your full medication list. Free for individuals.
Common Questions About Melanotan II
Melanotan II is not approved as a medicine in any country. The UK Medicines and Healthcare products Regulatory Agency (MHRA) and Australian Therapeutic Goods Administration (TGA) have explicitly warned against its sale and use. Sale through unlicensed channels may be illegal depending on jurisdiction.
Reported risks include new and changing moles, melanoma case reports, priapism, severe nausea and vomiting, facial pigmentation, cardiovascular effects, and serious infections from non-sterile injection. These are documented in regulator warnings and peer-reviewed case reports.
Melanotan I (afamelanotide) is a different molecule and is approved in some jurisdictions for erythropoietic protoporphyria under specialist supervision. Melanotan II is not approved anywhere. They should not be confused.
Speak to your doctor. Published case reports include melanomas diagnosed after melanotan II use. A clinical skin assessment is appropriate.
References
- UK Medicines and Healthcare products Regulatory Agency (MHRA). Melanotan: do not buy or use. Source.
- Therapeutic Goods Administration (Australia). Tanning injections containing melanotan. Source.
- Cardones AR, Grichnik JM. Alpha-melanocyte-stimulating hormone-induced eruptive naevi. Arch Dermatol. 2009;145(4):441-444. Source.
- Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228:34-36. Source.